Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 323.73% from the stock’s previous close.

A number of other equities analysts have also recently commented on HOTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Hoth Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Hoth Therapeutics has an average rating of “Hold” and a consensus price target of $4.50.

Hoth Therapeutics Stock Up 0.9%

Shares of NASDAQ HOTH opened at $1.18 on Monday. The firm has a market cap of $18.30 million, a price-to-earnings ratio of -1.11 and a beta of 0.63. The company’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $1.31. Hoth Therapeutics has a 52-week low of $0.66 and a 52-week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.20). Equities research analysts anticipate that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOTH. Lido Advisors LLC purchased a new position in Hoth Therapeutics during the third quarter worth approximately $32,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Hoth Therapeutics in the 3rd quarter worth $51,000. Geode Capital Management LLC raised its holdings in shares of Hoth Therapeutics by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after acquiring an additional 9,071 shares during the period. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics during the 3rd quarter valued at about $184,000. Finally, Citadel Advisors LLC acquired a new position in shares of Hoth Therapeutics during the 3rd quarter valued at about $232,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.